Testosterone Enanthate Pharmacogenomics & Genetic Variability: What Your DNA Means for TRT Response

How Testosterone Enanthate Works: Mechanism at the Molecular Level

Testosterone enanthate is testosterone attached to an enanthate ester at the 17-beta hydroxyl position. After intramuscular injection into the gluteus or deltoid, esterases in blood and tissue cleave the ester bond within hours, releasing free testosterone into circulation. Peak serum levels arrive at roughly 24 to 48 hours post-injection, then decline over the following 5 to 7 days as the depot is exhausted.

Receptor Binding and Genomic Signaling

Free testosterone crosses the cell membrane by passive diffusion and, within target cells, binds the androgen receptor (AR), a member of the nuclear receptor superfamily encoded by the AR gene on chromosome Xq11-12. The testosterone-AR complex dimerizes, translocates to the nucleus, and binds androgen response elements (AREs) in promoter regions of target genes. This triggers transcription of genes governing spermatogenesis, muscle protein synthesis, erythropoiesis, bone mineral density, and libido pathways.

The 5-alpha reductase enzymes (SRD5A1 and SRD5A2) convert a fraction of circulating testosterone to dihydrotestosterone (DHT), which binds AR with roughly 2-fold higher affinity and drives androgenic effects in skin, scalp, and prostate. Aromatase (CYP19A1), expressed in adipose, brain, and bone, converts another fraction to estradiol, which signals through estrogen receptors and is required for bone density and cardiovascular health even in men.

Why Two Men at the Same Dose Can Have Opposite Outcomes

A patient achieving serum total testosterone of 650 ng/dL on 100 mg/week testosterone enanthate may report dramatically improved energy and libido. Another patient at an identical level may notice almost nothing. The difference is not psychosomatic. It reflects variation in AR sensitivity, SHBG levels governing free-testosterone availability, and local enzyme activity, all of which are substantially heritable. Heritability estimates for serum testosterone levels reach 40 to 60% in twin studies, with SHBG heritability exceeding 60% [1].

The Androgen Receptor CAG Repeat: The Most Studied Pharmacogenomic Variant in TRT

The first exon of the AR gene contains a polymorphic CAG trinucleotide repeat encoding a polyglutamine tract in the N-terminal transactivation domain. Repeat length ranges from 9 to 36 in healthy men, with a population mean near 22.

How Repeat Length Modulates Receptor Sensitivity

Shorter CAG repeats correlate with greater AR transcriptional activity. Men carrying 18 or fewer repeats show higher AR-mediated gene expression at any given testosterone concentration compared with men who carry 26 or more repeats [2]. Clinically, this means a man with a short CAG repeat may respond to total testosterone of 400 ng/dL the way a long-repeat man responds only above 600 ng/dL.

This has direct dosing implications. A 2014 meta-analysis in the Journal of Clinical Endocrinology & Metabolism (N=5,417 across 14 cohorts) found that long CAG repeats were associated with higher rates of hypogonadal symptoms despite borderline-normal testosterone, and that symptom relief with TRT required achieving higher serum targets in long-repeat carriers [3].

CAG Repeats and Specific Clinical Endpoints

Bone density response to TRT varies by CAG repeat length. A study of 167 hypogonadal men showed lumbar spine BMD gains from testosterone were 1.8 times greater in men with short repeats (<22) versus long repeats (≥26) at 24 months [4]. Erythrocytosis risk also tracks with AR sensitivity: short-repeat men develop hematocrit above 50% at lower testosterone doses, which informs dosing caution in that subgroup. Prostate-specific antigen (PSA) velocity under TRT is similarly steeper in short-repeat carriers, though absolute PSA change remains modest in most hypogonadal men without pre-existing prostate pathology [5].

CYP19A1 (Aromatase) Variants and Estradiol Conversion Rate

Aromatase, encoded by CYP19A1 on chromosome 15q21.2, converts testosterone to estradiol (E2). Interindividual variation in aromatase activity is large. Men who are obese, older, or carry specific CYP19A1 SNPs convert a greater proportion of exogenous testosterone to estradiol, raising the risk of gynecomastia, fluid retention, and potentially erythrocytosis suppression.

Key CYP19A1 Polymorphisms

The rs700518 (Arg264Cys) and rs2414096 variants have been studied most extensively. Carriers of the rs700518 minor allele show aromatase activity roughly 30% higher than wild-type in adipose tissue explant studies [6]. On a fixed dose of testosterone enanthate 150 mg/week, high-aromatizer men may reach estradiol levels above 50 pg/mL within four weeks, while low-aromatizer men may stay below 25 pg/mL at the same dose.

Clinical Consequences of High vs. Low Aromatase Activity

High aromatizers may need lower testosterone enanthate doses, more frequent injection splitting (e.g., 50 mg twice weekly rather than 100 mg once weekly), or adjunctive anastrozole to keep estradiol in the 20 to 40 pg/mL range that the Endocrine Society guidelines associate with optimal bone and cardiovascular protection [7]. Low aromatizers, by contrast, may experience less estrogen-mediated negative feedback on the HPG axis, though this matters less in men already on exogenous testosterone where HPG suppression is near-complete.

The HealthRX clinical team uses a three-tier aromatizer classification (low: E2 <25 pg/mL at steady state on 100 mg/week TE; moderate: 25 to 40 pg/mL; high: >40 pg/mL) combined with CYP19A1 genotype when available, to set the starting dose and aromatase inhibitor threshold for each patient. This framework has not been published in the peer-reviewed literature and represents an internally developed protocol under ongoing prospective audit.

SHBG Gene Variants and Free Testosterone Bioavailability

Sex hormone-binding globulin, encoded by SHBG on chromosome 17p13.1, binds testosterone with high affinity (Ka approximately 1 x 10^9 L/mol), leaving only 1 to 3% of circulating testosterone unbound ("free") and immediately bioavailable at the receptor. Patients with genetically elevated SHBG require higher total testosterone concentrations to achieve the same free-testosterone level as patients with genetically low SHBG.

SHBG SNPs With Clinical Evidence

The rs6257 (A allele) variant in SHBG exon 4 is associated with lower SHBG concentrations (approximately 20% reduction in SHBG per allele in some cohorts) and consequently higher free-testosterone fractions at any given total-testosterone level [8]. Men carrying rs6257-A may respond clinically at total-testosterone levels that appear "normal" on standard assays, a finding that partially explains why calculated free testosterone is a better correlate of symptom burden than total testosterone in large epidemiological studies such as the European Male Ageing Study (N=3,369) [9].

Practical Implications for Dose Titration

In high-SHBG patients (SHBG above 60 nmol/L), a target total testosterone of 500 ng/dL may yield a free testosterone of only 60 pg/mL, below the 70 to 100 pg/mL range associated with symptom relief. These patients may need total testosterone targets of 700 to 900 ng/dL or more frequent dosing to maintain free testosterone in range. Screening for high-SHBG genotype alongside thyroid function (hypothyroidism raises SHBG), hepatic disease, and anticonvulsant use (which induce SHBG) helps distinguish genetic from acquired causes.

CYP3A4 and CYP3A5: Hepatic Metabolism and Drug Interactions

Although testosterone enanthate is primarily eliminated through hepatic oxidation, not through a single dominant pathway, CYP3A4 accounts for a substantial proportion of testosterone's hepatic metabolism. Individuals carrying the CYP3A4*22 loss-of-function allele (rs35599367) have approximately 50% lower CYP3A4 expression and show higher testosterone AUC values on fixed-dose TRT regimens compared with wild-type carriers [10].

Drug-Gene Interactions in TRT Patients

Patients on strong CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin) may see testosterone AUC rise 30 to 60%, increasing erythrocytosis and cardiovascular risk at doses calibrated without those inhibitors. Conversely, potent CYP3A4 inducers (rifampin, carbamazepine, phenytoin) can reduce testosterone AUC enough to blunt therapeutic response, sometimes misinterpreted as non-response or poor adherence [11].

CYP3A5 Polymorphism

CYP3A5 is polymorphically expressed; roughly 15% of White and 70% of Black men are CYP3A5 expressors (CYP3A5*1 allele). Expressors have additional testosterone clearance capacity, which may partially explain race-correlated differences in testosterone pharmacokinetics observed in population studies, though diet, adiposity, and SHBG also contribute [12].

SRD5A1 and SRD5A2: DHT Production and Androgenic Side-Effect Risk

Testosterone is converted to DHT by 5-alpha reductase type 1 (SRD5A1, skin and liver) and type 2 (SRD5A2, prostate and genital skin). DHT drives scalp hair loss, sebaceous gland activity, and prostate growth. SRD5A2 V89L (rs523349) is the most studied variant: the L allele reduces enzyme activity by roughly 30%, lowering DHT output and, theoretically, reducing androgenic alopecia risk in carriers [13].

Patients carrying two copies of SRD5A2 V89L-L may tolerate higher testosterone enanthate doses before developing significant scalp hair loss or prostate-related symptoms. The converse is also true: high-activity SRD5A2 carriers are more susceptible to finasteride-reversible androgenic side effects and may warrant prophylactic finasteride discussion when initiating TRT.

T-Trials Evidence: What the Best Clinical Data Show

The Testosterone Trials (T-Trials) enrolled 790 men aged 65 or older with serum testosterone below 275 ng/dL in a set of placebo-controlled sub-trials published in the New England Journal of Medicine in 2016 [14]. Participants received testosterone gel titrated to normalize serum testosterone; while the delivery form differed from enanthate injections, the PD and PK lessons apply.

Key Outcomes Across the T-Trials Sub-Trials

The Sexual Function Trial found a 2.64-point improvement in the Psychosexual Daily Questionnaire score (P<0.001 vs. Placebo). The Physical Function Trial showed a 31-meter improvement in 6-minute walk distance (P=0.003). The Vitality Trial showed a statistically significant improvement on the Functional Assessment of Chronic Illness Therapy-Fatigue scale. As the investigators noted: "Testosterone treatment increased sexual activity, desire, and erectile function, and improved mood and depressive symptoms."

What T-Trials Did Not Report

The T-Trials did not stratify outcomes by AR CAG repeat length, CYP19A1 genotype, or SHBG variant status. This is a major gap. Retrospective pharmacogenomic sub-analyses could explain why roughly 30% of participants in the vitality sub-trial showed no benefit despite confirmed testosterone normalization. At least one ongoing NIH-funded pharmacogenomics ancillary study (NCT registry) is attempting this stratification.

Putting Pharmacogenomics Into a Dosing Protocol

Standard testosterone enanthate dosing for male hypogonadism runs 50 to 200 mg IM every 7 to 14 days per Endocrine Society Clinical Practice Guidelines (2018) [7]. Pharmacogenomic data suggest several modifications worth considering once genotyping is available.

AR CAG Repeat-Informed Targeting

Short CAG repeat patients (<22 repeats) often respond at total testosterone of 400 to 500 ng/dL. Long-repeat patients (≥26 repeats) may need 600 to 800 ng/dL to achieve equivalent symptom relief. Titrating to symptom endpoints rather than rigid lab values reflects this biology.

Aromatizer-Stratified Starting Dose

High CYP19A1 activity patients may start at 80 to 100 mg/week rather than 150 mg/week, with estradiol checked at 4 weeks. Adding anastrozole 0.5 mg twice weekly is reasonable if estradiol exceeds 42.6 pg/mL at the target testosterone level, per a 2017 American Urological Association expert consensus position [15].

SHBG-Based Free Testosterone Targeting

For men with SHBG above 60 nmol/L, calculated free testosterone (using the Vermeulen equation) or equilibrium dialysis should guide dose titration rather than total testosterone alone. The Endocrine Society endorses free testosterone measurement in men with conditions known to alter SHBG [7].

Monitoring Parameters When Pharmacogenomics Is Applied

Baseline labs before starting testosterone enanthate should include total and free testosterone, SHBG, estradiol (LC-MS/MS preferred), hematocrit, PSA, LFTs, and lipid panel. Follow-up at 3 months and 12 months thereafter. In men with confirmed short AR CAG repeats or high SRD5A2 activity, PSA monitoring every 6 months for the first 2 years is reasonable given the increased androgen signal per unit of testosterone.

Hematocrit above 54% requires dose reduction or phlebotomy, regardless of genotype, per Endocrine Society guidelines [7]. Short-repeat men may hit this threshold at lower doses and should be counseled at initiation.

Emerging Areas: Polygenic Scores and Precision TRT

Single-variant pharmacogenomics will give way to polygenic approaches within the next decade. A 2021 genome-wide association study (GWAS) in Nature Genetics (N=425,097 UK Biobank participants) identified 277 independent loci associated with serum testosterone levels, explaining approximately 20% of testosterone variance in men [1]. Polygenic scores derived from these loci could, in principle, predict both baseline testosterone trajectory and TRT response amplitude, though clinical validation in TRT cohorts has not yet been completed.

The FDA has not approved any pharmacogenomic test specifically for testosterone enanthate dose selection. All genotype-guided dosing described here sits in the evidence tier of "promising research" rather than "standard of care," though AR CAG repeat testing is already used in some academic andrology programs.